(株)免疫生物研究所の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|---|---|---|
東証GRT | 医薬品 | 4570/E00986 | Immuno-Biological Laboratories Co.,Ltd. |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|---|---|---|---|---|---|---|---|---|
2017/05/02 | 日証協 | 273,685株 | -1.23% | 700株 | -88.52% | 339,437株 | -0.35% | 1,800株 | +5.88% |
2017/04/28 | 日証協 | 277,085株 | -1.98% | 6,097株 | -85.45% | 340,637株 | -0.56% | 1,700株 | -91.67% |
2017/04/21 | 日証協 | 282,688株 | +23.07% | 41,897株 | -54.56% | 342,540株 | +9.95% | 20,400株 | -61.15% |
2017/04/14 | 日証協 | 229,691株 | +6.14% | 92,200株 | -44.09% | 311,543株 | +6.5% | 52,515株 | -22.33% |
2017/04/07 | 日証協 | 216,394株 | +68.63% | 164,894株 | +154.52% | 292,521株 | +35.9% | 67,613株 | +23.45% |
2017/03/31 | 日証協 | 128,324株 | +35.92% | 64,786株 | +206.88% | 215,249株 | +0.43% | 54,771株 | +360.26% |
2017/03/24 | 日証協 | 94,411株 | -1.66% | 21,111株 | -29.16% | 214,338株 | -2.14% | 11,900株 | -59.39% |
2017/03/17 | 日証協 | 96,000株 | +22.61% | 29,800株 | +105.52% | 219,027株 | -5.73% | 29,301株 | -70.14% |
2017/03/10 | 日証協 | 78,300株 | 0% | 14,500株 | 0% | 232,338株 | +1.35% | 98,120株 | +9999.99% |
2017/03/03 | 日証協 | 78,300株 | -3.69% | 0株 | -100% | 229,238株 | -1.25% | 500株 | -78.54% |
2017/02/24 | 日証協 | 81,300株 | +0.74% | 600株 | 0% | 232,138株 | +0.62% | 2,330株 | +133% |
2017/02/17 | 日証協 | 80,700株 | -2.65% | 0株 | 0% | 230,708株 | +15.39% | 1,000株 | -97.04% |
2017/02/10 | 日証協 | 82,900株 | -0.48% | 0株 | -100% | 199,944株 | -8.55% | 33,800株 | +604.17% |
2017/02/03 | 日証協 | 83,300株 | -2.8% | 1,000株 | -72.22% | 218,644株 | +0.96% | 4,800株 | +128.57% |
2017/01/27 | 日証協 | 85,700株 | +6.2% | 3,600株 | -10% | 216,574株 | +1.12% | 2,100株 | -87.66% |
2017/01/20 | 日証協 | 80,700株 | +1.25% | 4,000株 | +344.44% | 214,174株 | -3.38% | 17,013株 | +1316.57% |
2017/01/13 | 日証協 | 79,700株 | -19.9% | 900株 | 0% | 221,667株 | -4.24% | 1,201株 | -64.68% |
2017/01/06 | 日証協 | 99,500株 | -3.68% | 0株 | -100% | 231,471株 | +0.87% | 3,400株 | -73.23% |
2016/12/30 | 日証協 | 103,300株 | -20.35% | 2,200株 | -33.33% | 229,481株 | -1.54% | 12,701株 | +535.05% |
※株式分割は考慮していませんのでご注意ください。